A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors
暂无分享,去创建一个
[1] T. Sauter,et al. Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma , 2018, npj Systems Biology and Applications.
[2] O. Micheau,et al. Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy , 2017, Antibodies.
[3] H. Gronemeyer,et al. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells , 2017, Cell Death and Disease.
[4] E. Szliszka,et al. Targeting Apoptotic Activity Against Prostate Cancer Stem Cells , 2017, International journal of molecular sciences.
[5] Jiong Cai,et al. A novel humanized anti‐tumor necrosis factor‐related apoptosis‐inducing ligand‐R2 monoclonal antibody induces apoptotic and autophagic cell death , 2017, IUBMB life.
[6] J. Lambert,et al. Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review , 2017, Advances in Therapy.
[7] C. Dumontet,et al. Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.
[8] A. Farooqi,et al. Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology , 2017, Oncology reviews.
[9] William A. Hammond,et al. Emerging therapeutic agents for lung cancer , 2016, Journal of Hematology & Oncology.
[10] 黄长江,et al. Covalent linkers in antibody-drug conjugates and methods of making and using the same , 2016 .
[11] J. Ji,et al. Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells. , 2016, Oncology Report.
[12] Shery Jacob,et al. A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.
[13] Paul Polakis,et al. Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.
[14] L. Lou,et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity , 2015, Breast Cancer Research and Treatment.
[15] M. Dorywalska,et al. Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy , 2015, PloS one.
[16] B. Tomczuk,et al. Current ADC Linker Chemistry , 2015, Pharmaceutical Research.
[17] J. Hou,et al. A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma , 2014, American journal of hematology.
[18] Paul Polakis,et al. Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.
[19] Juan Shi,et al. TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis , 2013, Cancer Immunology, Immunotherapy.
[20] Juan Shi,et al. A novel anti‐DR5 chimeric antibody and epirubicin synergistically suppress tumor growth , 2012, IUBMB life.
[21] Juan Shi,et al. Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice. , 2011, Cancer letters.
[22] L. Maestre,et al. Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. , 2011, Immunology letters.
[23] B. Mayer,et al. Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer , 2010, Molecular Cancer Therapeutics.
[24] Juan Shi,et al. Targeting a Novel N-terminal Epitope of Death Receptor 5 Triggers Tumor Cell Death* , 2010, The Journal of Biological Chemistry.
[25] D. Benjamin,et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.
[26] Ya-xi Zhang,et al. TRAIL receptor mediates inflammatory cytokine release in an NF-κB-dependent manner , 2009, Cell Research.
[27] P. Senter. Potent antibody drug conjugates for cancer therapy. , 2009, Current opinion in chemical biology.
[28] Eeva-Liisa Eskelinen,et al. Autophagy: a lysosomal degradation pathway with a central role in health and disease. , 2009, Biochimica et biophysica acta.
[29] V. Deretic,et al. Unveiling the roles of autophagy in innate and adaptive immunity , 2007, Nature Reviews Immunology.
[30] Ronald Koschny,et al. The promise of TRAIL—potential and risks of a novel anticancer therapy , 2007, Journal of Molecular Medicine.
[31] Juan Shi,et al. Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice. , 2006, Cancer research.
[32] Yabin Guo,et al. A Novel Anti-human DR5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase-dependent and Caspase-independent Cell Death* , 2005, Journal of Biological Chemistry.
[33] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[34] Damon L. Meyer,et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.
[35] G. Gores,et al. Is TRAIL hepatotoxic? , 2001, Hepatology.
[36] S. S. Strom,et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.
[37] Henning Walczak,et al. TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.
[38] R. Gentz,et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.
[39] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[40] A. Ciechanover. Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. , 2013, Bioorganic & medicinal chemistry.
[41] Juan Shi,et al. 2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.